McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition
|
|
- Beryl Price
- 6 years ago
- Views:
Transcription
1 Additional references (web) w1 McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989 Jan 26;320(4): w2 Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992 Sep;166(3): w3 Sheikh RA, Yasmeen S, Pauly MP, Trudeau WL. Pseudomembranous colitis without diarrhea presenting clinically as acute intestinal pseudo-obstruction. J Gastroenterol 2001 Sep;36(9): w4 HPA: CDI Working group. Questions and answers about the laboratory diagnosis of Clostridium difficile infection, March w5 JS Brazier, BI Duerden. Guidelines for optimal surveillance of Clostridium difficile infection in hospitals. Commun Dis Public Health 1998; 1: w6 Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003;51: w7 Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004;171:51-8. w8 Fishman N. Antimicrobial stewardship. Am J Med 2006;119(6 suppl 1):S w9 Knox K, Lawson W, Dean B, Holmes A. Multidisciplinary antimicrobial management and the role of the infectious diseases pharmacist--a UK perspective. J Hosp Infect 2003;53:
2 w10 HZilberberg MD, Nathanson BH, Sadigov S, Higgins TL, Kollef MH, Shorr AF. Epidemiology and outcomes of Clostridium difficile-associated disease among patients on prolonged acute mechanical ventilation. Chest 2009 Sep;136(3): w11 Sundram F, Guyot A, Carboo I, Green S, Lilaonitkul M, Scourfield A. Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors. J Hosp Infect 2009 Jun;72(2): w12 Wilcox MH, Fawley WN, Wigglesworth N, Parnell P, Verity P, Freeman J. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 2003 Jun;54(2): w13 Boyce JM, Havill NL, Otter JA, McDonald LC, Adams NM, Cooper T et al. Impact of hydrogen peroxide vapor room decontamination on Clostridium difficile environmental contamination and transmission in a healthcare setting. Infect Control Hosp Epidemiol 2008 Aug;29(8): w14 Brooks SE, Veal RO, Kramer M, Dore L, Schupf N, Adachi M. Reduction in the Incidence of Clostridium difficile-associated Diarrhea in an Acute Care Hospital and a Skilled Nursing Facility following Replacement of Electronic Thermometers with Single-Use Disposables. Infect Control Hosp Epidemiol 1992 Feb;13(2): w15 Brooks S, Khan A, Stoica D, Griffith J, Friedeman L, Mukherji R et al. Reduction in vancomycin-resistant Enterococcus and Clostridium difficile infections following change to tympanic thermometers. Infect Control Hosp Epidemiol 1998 May;19(5): w16 Gouliouris T, Forsyth DR, Brown NM. Clostridium difficile-associated diarrhoea (CDAD): new and contentious issues. Age Ageing. 2009;38:
3 w17 Viashavni V. Established and potential risk factors for Clostridium difficile infection. Indian J Med Microbiol 2009;27(4): w18 Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102: w19 Parkes GC, Sanderson JD, Whelan K. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infect Dis 2009;9: w20 Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005;173: w21 Kato H, Kato H, Nakamura M, Nakamura A. A case of toxic megacolon secondary to Clostridium difficile-associated diarrhea worsened after administration of an antimotility agent and molecular analysis of recovered isolates. J Gastroenterol 2007;42: w22 Steinbakk M, Lingaas E, Carlstedt-Duke B, et al. Faecal concentration of ten antibiotics and influence on some microflora-associated characteristics (MACS). Microbial Ecology in Health and Disease 1992;5: w23 Baines SD, O'Connor R, Freeman J, Fawley WN, Harmanus C, Mastrantonio P et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008 Nov;62(5): w24 Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995 Oct;36(4): w25 Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium 3
4 difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008 Jul 1;47(1): w26 Johnson S, Peterson LR, Gerding DN. Intravenous metronidazole and Clostridium difficile-associated diarrhea or colitis. J Infect Dis 1989;160: w27 Lagrotteria D, Holmes S, Smieja M, Smaill F, Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43: w28 Herpers BL, Vlaminckx B, Burkhardt O, Blom H, Biemond-Moeniralam HS, Hornef M, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009;48: w29 Hu M, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009;136: w30 Do AN, Fridkin SK, Yechouron A, Banerjee SN, Killgore GE, Bourgault AM, et al. Risk factors for early recurrent Clostridium difficile associated diarrhea. Clin Infec Dis 1998;26: w31 Wilcox MH, Fawley WN, Settle CD, Davidson A. Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection? J Hosp Infect 1998;38: w32 Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile associated diarrhoea episodes by serial therapy with vancomycin and rifaximin. Clin Infec Dis 2007;44: w33 Department of Health. Demand management plan for immunoglobulin use. 2nd ed. London: DoH,
5 w34 Macconnachie AA, Fox R, Kennedy DR, Seaton RA. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 2009 Nov;102(11): w35 Tedesco F, Markham R, Gurwith M, Christie D, Bartlett JG. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978;2:
6 Many thanks to the Reviewers and Editors for their constructive comments. Our responses are outlined below. Reviewer comments Comment My main criticism is that the referencing needs to be improved there is too much use of review articles instead of source studies. Also, the choice of which statements to reference is inconsistent, including whether w or main references are utilised. Some (but not all) such instances are included below. Pg % of hospital inpatients Some studies have shown lower carriage prevalences need to be careful when summarising such data, as the type of patient, hospital, length of stay etc will all potentially influence the data. Pg 4 In suspected cases of silent C. difficile infection, occurring without diarrhoea, other diagnostic procedures such as endoscopy or an abdominal CT scan may be required. Should point out here that such cases may represent very severe infection associated with ileus/toxic megacolon. Pg 5 C. difficile infection has been estimated to increase the duration of hospital stay by an average of 21 days. Old (but (NHS) data, not recently collected may be shorter increased lengths of stay now. Pg 5. In the introductory paragraph to the Prevention section, there is no mention of the potential benefit of using molecular surveillance techniques to identify case clusters/transmission. There is circumstantial evidence that CDI reports in England have declined once there was widespread access to/uptake of this approach (as an adjunct to mandatory surveillance, which is also not mentioned). Hence, enhanced surveillance is an important part of CDI control (prevention). Response The references have been thoroughly expanded and revised, including utilisation of web vs. print citations. Specific instances are addressed below. C. difficile may be cultured from the stool of 3% of healthy adults, and as many as 35% of hospital inpatients. 3 Some studies have shown lower rates of nosocomial colonisation, which may vary depending on patient population, length of hospital stay and local infection control procedures. w1,w2 Paragraph revised, with additional reference: The spectrum of gastrointestinal disease associated with C. difficile infection ranges from mild diarrhoea to fulminant colitis. Some silent infections present with abdominal pain and distension, in the absence of significant diarrhoea. These features may indicate severe disease, causing ileus or toxic megacolon. w3 See also response to Editor comment [6]. C. difficile infection has been estimated to increase the duration of hospital stay by an average of 21 days, 16 although more recent studies have suggested a less pronounced effect. w10,w11 In the UK, reporting of C. difficile infections to the HPA is part of a mandatory surveillance scheme for healthcare associated infections. At a local level, surveillance of C. difficile infections is key to identifying outbreaks, and initiating control measures in a timely fashion. 6 Typing of C. difficile isolates and molecular surveillance techniques may assist in the investigation of apparent increases in cases, and improve the understanding of the transmission of epidemic strains within and between health care institutions. w5,7 Added to the Summary Points box: Surveillance of C. difficile infection at national and local levels is critical for guiding the implementation of control measures 6
7 This should thus also be included in the summary points box. Pg 5 Many authors have produced hit-lists blaming different antibiotics for their potential to cause C. difficile infection, but this approach is not without problems. Should emphasise the confounding due to duration of antibiotics, numbers of antibiotics and, crucially, exposure to C. difficile (Wilcox MH, Freeman J. Epidemic Clostridium difficile. N Engl J Med 2006;354: ). Pg 8 but the study suffered from major methodological flaws limiting the generalisability of the results. This statement should ideally be referenced as these major drawbacks were published. Wilcox MH, Sandoe JA. Probiotics and diarrhea: Data are not widely applicable. BMJ 2007;335:171. Pg 6-7 UK National Guidelines therefore make various recommendations with significantreductions in rates of C. difficile infection. The use of a review article (w9) as the sole refernce for these statements is not good practice. Key points should be individually referenced e.g. use of chlorinecontaining cleaning agents, disposable thermometers, etc. Pg 7 In a large outbreak, it may not be possible to isolate affected patients in single rooms with en suite facilities, and it may then be necessary to cohort nurse them in a dedicated area of a ward. This may be true in high endemicity settings not just outbreaks. Also, should link here to the sub-optimal PPV mentioned earlier i.e. risk of managing false-positive cases with true Although the use of fluoroquinolones has been linked to the spread of the ribotype 027 strain, risk analyses have been confounded by antibiotic polypharmacy, duration of antibiotic treatment, and infection control practices. 13,14 See also response to Editor comment [7]. Reference added, with thanks. 24 C. difficile spores can survive in the environment for months or years, and environmental contamination has been linked to the spread of C. difficile infection in healthcare settings. 17 UK National Guidelines therefore make various recommendations for C. difficile prevention through environmental decontamination: 1 cleaning of rooms or bed spaces of patients with C. difficile infection should be conducted daily using chlorinecontaining cleaning agents; w12 commodes, toilets and bathroom areas should be cleaned after each use; and when an infected patient has been discharged, the room and mattress should be thoroughly cleaned using chlorine-containing cleaning agents or vaporised hydrogen peroxide. w13 Please note also expanded discussion of isolation measures, and responses to Editor comments [8] and [9] on hand washing and electronic thermometers. There is no RCT or systematic review evidence assessing the value of isolation measures in preventing C. difficile infection, but a systematic review of isolation in the hospital management of methicillin resistant Staphylococcus aureus (MRSA) suggested its effectiveness as part of a broader infection control strategy. 20 UK National Guidelines recommend that patients with potentially infective diarrhoea should be moved immediately into a single room with en suite facilities, 1 but this practice is not without difficulties. For example, moving frail elderly 7
8 cases. Pg 9 UK surveillance data supports the emergence of reduced susceptibility to metronidazole in some C. difficile isolates, but the clinical significance of this is unclear. w1 is not the source reference for this observation. Pg 9. Which antibiotics are used to treat C. difficile infection There is evidence that response time to vancomycin may be shorter than to metronidazole. This is not mentioned. Pg 10 and because there is concern that overuse of vancomycin may result in the selection of vancomycin resistant Enterococci. Actually, there is reasonable evidence that metronidazole is a risk factor for vancomycin resistant enterococcal overgrowth. Again, w1 is not the correct reference for such a statement. Pg 11 The risk of recurrence following a single episode is significant, with up to 35% of patients experiencing at least a second episode after treatment with either metronidazole or vancomycin. This unreferenced rate is higher than is generally accepted (~20%). Risk factors include Previous CDI should be included here. Pg 11 Patients may continue to remain C. difficile toxin positive despite clinical cure. Key point, but not referenced. Pg 13 Intravenous immunoglobulin may therefore benefit a small group of patients patients with C. difficile infection may increase the risk of delirium, and its associated adverse effects. w16 In a large outbreak, or settings with high endemicity, it may not be possible to isolate affected patients in single rooms. The creation of C. difficile isolation wards in hospitals with high levels of disease proved successful in certain wellpublicised outbreaks. 6,21 Since the positive predictive value of C. difficile toxin immunoassays is sub-optimal, however, transferring patients to cohort areas runs the risk of putting individuals without C. difficile (false positives) at a greatly increased risk of acquiring the infection. Reference added. w23 Retrospective and prospective observational studies have also shown the response time to vancomycin to be shorter than to metronidazole, which may be important in patients with severe disease. w24,w25 Paragraph revised, with additional reference: UK National Guidelines therefore still recommend oral metronidazole for initial treatment in these patient groups, because it is cheaper than oral vancomycin, and because of concern that overuse of vancomycin may result in the selection of vancomycin resistant Enterococci. 1 Observational data suggest, however, that metronidazole, as well as vancomycin, may promote persistent overgrowth of vancomycin resistant Enterococci. 28 Paragraph revised: The risk of recurrence following a single episode is significant, with 8-50% of patients experiencing at least a second episode after treatment with either metronidazole or vancomycin. 3 Paragraph revised: Risk factors include previous relapses, age greater than 65 years, severe underlying illness, and additional antibiotic use after treatment for C. difficile infection has been stopped. w29,w30 Reference added. 31 Please see response to Editor comment [12]. 8
9 with multiple recurrences, but there are no RCTs to support its adoption and issues such as cost and availability may preclude its use. No source references are supplied. Also, worth pointing out that this indication is included in the DoH list of indications for prescribing of iv immunoglobulin. Editor comments Comment 1. Please read this letter in conjunction with a word document that I shall send attached to a separate . The document is a copy of your submitted manuscript, in which I have used the track changes word tool to reduce the word count, to indicate some style changes that we would like you to make and to ask questions at relevant points. Questions, explanations and requests for further information are enclosed in [square brackets] and may be highlighted. 2. In the first sentence of the introduction please qualify whether you refer to incidence of C. diff infection or diarrhea increasing. 3. In the introduction you mention the previously uncommon but highly virulent strain, but then you do not mention it again, which is odd. Perhaps it would be better to omit mention of it at all. 4. We suggest bringing up one point from the conclusion and putting it in the introduction. Many cases of infection could be prevented by the combination of prudent antibiotic prescribing and vigorous application of infection control measures. 5. In the section on who becomes infected please change up to to as many as. A reader has repeatedly criticized us for using the term up to, which he says is a journalistic term, so we try to avoid using it now. Are you able to give readers an estimate of the prevalence of C. diff colonization in the community? Response Stylistic changes accepted. Exception: Community-associated infections have increased... is not equivalent to Community-associated infections have been increasingly recognised... In this instance, the original wording has therefore been maintained. Please see responses to specific questions (below). Paragraph revised: The incidence of Clostridium difficile infection in the UK has increased since the late 1990s. 1 Conversely, it might seem odd not to mention the ribotype 027 strain at all! Please note response to Reviewer comment on paragraph headed: How can antibiotic stewardship help prevent C. difficile infection? The use of fluoroquinolones has been linked to the spread of the ribotype 027 strain, but risk analyses may be confounded by antibiotic polypharmacy, duration of antibiotic treatment, and infection control practices. 13,14 Would it please be OK to leave this point in the conclusion, but abridge as follows? Many cases of C. difficile infection could be prevented by prudent antibiotic prescribing and vigorous infection control measures, which may also reduce other healthcare associated infections, and limit the spread of multi-resistant organisms such as MRSA and vancomycin resistant Enterococci. Whilst RCT evidence has emerged to support guidance on the initial antibiotic therapy of C. difficile infection, more data are urgently needed to advise on the management of refractory, fulminant and recurrent disease. We think this reads better, especially if the review is to be shortened. Stylistic change accepted. We have stated a figure of 3% for C. diff colonization of healthy adults, who of course reside in the community. Please also note response to Reviewer comment on paragraph headed: Who becomes infected with C. difficile? 9
10 6. In the section How does C. difficile infection present and how is it diagnosed? please mention how silent infection presents in the first part after describing the spectrum of GI disease. At the end of the section please say what endoscopy and/or CT would be expected to show in C. diff infection. 7. Under..antibiotic stewardship please tell us which agents within the fluoroquinolone class have been associated with higher likelihood of C. diff infection. ( The contribution of fluoroquinolones to C. difficile infection is still debated,7 but observational data suggest that different agents within this class have different propensity to cause C. difficile infection. ) 8. Where you say, Alcohol-based hand gels are less effective at reducing contamination with C. difficile spores than washing with soap and water, please either say what studies have shown this or say who recommends it.the reference w1 is to Department of health guidelines, which doesn t give the reader an idea of the strength of evidence underlying the statement. 9. Where you talk about replacing digital thermometers with disposable thermometers because this has been associated with significant reductions in C. diff infection rates please can you tell the reader what sort of study showed this, how big the reduction in infection was and if the results can be generalised. 10. Please include more points in your summary points. We suggest the following four points: The incidence of Clostridium difficile infection has increased in the last decade Strategies to control C. difficile infection Paragraph revised: In suspected cases of silent C. difficile infection, an endoscopy or abdominal CT scan may be required. Characteristic findings include thickening of the colonic wall, dilatation and pseudomembrane formation. 2 Please also note response to Reviewer comment on paragraph headed: How does C. difficile infection present and how is it diagnosed? Paragraph revised: In addition, observational data suggest that different fluoroquinolones may have different propensities to cause C. difficile infection, with gatifloxacin associated with the highest risk. 9 Hand washing is paramount in the prevention of most hospital-acquired infections ( Alcoholbased hand gels are highly effective against non-spore forming organisms, but they do not kill C. difficile spores or remove them from the hands. Experimental studies examining different hand hygiene methods have shown that alcohol-based hand gels are significantly less effective at reducing contamination with C. difficile spores than washing with soap and water. 17,18 UK National Guidelines therefore recommend that healthcare workers wash their hands before and after contact with patients with suspected or proven C. difficile infection, and that disposable gloves and aprons be used whenever handling body fluids and caring for such patients. 1 As stated, the recommendation comes from UK National Guidelines 1, and the National Patient Safety Agency CleanYourHands campaign. Replacing electronic oral and rectal thermometers (which may become contaminated with C. difficile spores, and then inoculate them directly into the gastrointestinal tract) with disposable thermometers has been associated with significant reductions in rates of C. difficile infection. w14 A prospective randomised crossover study involving 20 nursing units reported a significantly lower rate of nosocomial C. difficile infection with disposable thermometer use (0.16 per 1,000 patient days) compared with electronic thermometer use (0.37 per 1,000 patient days, relative risk [RR] = 0.44; 95% confidence interval ), 19 and a similar reduction was reported from an observational study comparing rates before and after the introduction of tympanic thermometers. w15 Changes accepted, but instead of... Strategies to control C. difficile infection depend largely on prevention... we have included the following, as requested by the Reviewer comment on the paragraph headed: Prevention. 10
11 depend largely on prevention. C. difficile infection may be prevented by prudent antibiotic prescribing, correct hand hygiene and use of personal protective equipment, environmental decontamination and isolation / cohort nursing Nationally agreed protocols provide recommend treating C. difficile infection initially with oral vancomycin or metronidazole according to severity of disease, and escalating treatment in the event of non-response 11. Please look at the third point in the tips for non specialists box. If you do not mention this aspect of management in the main text then please remove this point. 12. We trust that you have seen the recent NEJM editorial and RCT on this subject. The editorial makes the important point about the management of C. difficile infection that it s an antibiotic-associated condition for which antibiotics are the mainstay of treatment, and that although antibiotics are effective at inhibiting C. difficile and treating symptoms, they prevent the reestablishment of normal bowel flora, which means that a substantial proportion of patients suffer recurrent infections after the cessation of treatment. You might make this link in your article. The RCT examines two neutralizing human monoclonal antibodies against C. difficile toxins A and B. Might you update your treatment section to mention this RCT? 13. General point: Due to space constraints in the print journal we set the word limit at 2000 words (excluding text in boxes, tables, figure Surveillance of C. difficile infection at national and local levels is critical for guiding the implementation of control measures Please note the paragraph headed: Medical Management. This is an important point. Patients with C. difficile infection are prone to developing electrolyte imbalance, dehydration, malnutrition and pressure sores, and it is therefore essential to optimise their supportive medical care. Following outbreaks at Maidstone and Tunbridge Wells NHS Trust in , the UK Healthcare Commission was critical of the quality of general management of patients with C. difficile infection, including inadequate monitoring and doctor review, poor fluid replacement and nutritional support, and lack of multi-disciplinary assessment. 6 Updated Ongoing Research box to include monoclonal antibodies: There is considerable interest in the development of monoclonal antibodies and toxin-specific vaccines for the prevention or treatment of C. difficile infection, and Tolevamer, a novel toxin-binding polymer, is undergoing clinical trials Revised paragraph headed: How do recommendations differ for recurrent disease? Low levels of serum antibodies against C. difficile Toxin A correlate with the risk of recurrent C. difficile infection, 33 and a recent phase 2 RCT demonstrated a significant reduction in C. difficile recurrence in patients treated with experimental monoclonal antibodies against toxins A and B. 34 Pooled intravenous immunoglobulin may also be able to neutralise these toxins, and a small case series reported a successful clinical response to intravenous immunoglobulin in 3 out of 5 patients with recurrent C. difficile infection. 35 Although recommended in the UK Department of Health Clinical Guidelines for Immunoglobulin Use, for selected patients with multiply recurrent C. difficile infection in whom all other treatments have failed or are inappropriate, there are no RCTs to support the use of intravenous immunoglobulin, and issues such as cost and availability may preclude its widespread adoption. w33 Revised paragraph headed: How is recurrent C. difficile infection diagnosed? Paradoxically, the antibiotics used to treat C. difficile infection may themselves interfere with the reestablishment of the normal colonic flora, contributing to the propensity for recurrent disease. Sections which may be removed to shorten the print version to around 2000 words have been highlighted in grey. Please note that this inevitably includes some 11
12 legends and the reference list). Often after addressing our and reviewers points authors find that the review exceeds 2000 words. Often that s okay; it may be printed in its entirety on bmj.com but you will need to highlight discrete chunks that could be omitted in the print version. Please do not supply us with a long and a short version. We require only one version but if it is too long possible cuts should be identified. areas expanded in response to Reviewer and Editor comments. Please also note that the reference list will be affected if the highlighted areas are excised! 12
Overview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases
Overview of C. difficile infections Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Conflicts of Interest I have no financial conflicts of interest related to this topic and presentation.
More informationClostridium difficile Colitis
Update on Clostridium difficile Colitis Fredrick M. Abrahamian, D.O., FACEP Associate Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA
More informationClostridium difficile Infection Prevention. Basics of Infection Prevention 2-Day Mini-Course 2012
Clostridium difficile Infection Prevention Basics of Infection Prevention 2-Day Mini-Course 2012 2 Objectives Describe the etiology and epidemiology of C. difficile infection (CDI) Review evidence-based
More informationRunning head: CLOSTRIDIUM DIFFICILE 1
Running head: CLOSTRIDIUM DIFFICILE 1 Clostridium difficile Infection Christy Lee Fenton Mountainland Applied Technology College CLOSTRIDIUM DIFFICILE 2 Clostridium difficile Infection Approximately 200,000
More informationClostridium difficile
Clostridium difficile A Challenge in Long-Term Care Andrew E. Simor, MD, FRCPC Sunnybrook Health Sciences Centre University of Toronto Hosted by Paul Webber paul@webbertraining.com Objectives to understand
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationClostridium Difficile Primer: Disease, Risk, & Mitigation
Clostridium Difficile Primer: Disease, Risk, & Mitigation KALVIN YU, M.D. CHIEF INTEGRATION OFFICER, SCPMG/SCAL KAISER PERMANENTE ASSOCIATE PROFESSOR INFECTIOUS DISEASE, COLLEGE OF GLOBAL PUBLIC HEALTH,
More informationPreventing Clostridium difficile Infection (CDI)
1 Preventing Clostridium difficile Infection (CDI) All Hands on Deck to Reduce CDI Skill Nursing Facility Conference July 28, 2017 Idamae Kennedy, MPH,BSN,RN,CIC Liaison Infection Preventionist Healthcare
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationIncidence of hospital-acquired Clostridium difficile infection in patients at risk
Baptist Health South Florida Scholarly Commons @ Baptist Health South Florida All Publications 5-20-2016 Incidence of hospital-acquired Clostridium difficile infection in patients at risk Christine Ibarra
More informationClinical Spectrum of Disease. Clinical Features. Risk Factors. Risk of CDAD According to Antibiotic Class. Fluoroquinolones as Risk Factor for CDAD
Clinical Features Range from mild diarrhea to severe colitis and death Common clinical symptoms include Watery diarrhea Fever Loss of appetite Nausea Abdominal pain/tenderness Less common ileus CDC Fact
More informationEducational Module for Nursing Assistants in Long-term Care Facilities: Preventing and Managing Clostridium difficile Infections
Educational Module for Nursing Assistants in Long-term Care Facilities: Preventing and Managing Clostridium difficile Infections Minnesota Department of Health Infectious Disease Epidemiology, Prevention,
More informationClostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU
Clostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU Disclosures I am not Tom Riley The Fidaxomicin guys brought me dinner once Outline ASID/AICA position
More informationReply to Fabre et. al
Reply to Fabre et. al L. Clifford McDonald, 1 Stuart Johnson, 2,3 Johan S. Bakken, 4 Kevin W. Garey, 5 Ciaran Kelly, 6 Dale N. Gerding, 2 1 Centers for Disease Control and Prevention, Atlanta, Georgia;
More informationHealthcare-associated Infections Annual Report December 2018
December 2018 Healthcare-associated Infections Annual Report 2011-2017 TABLE OF CONTENTS INTRODUCTION... 1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS... 2 MRSA SURVEILLANCE... 3 CLOSTRIDIUM
More informationAntibiotic Stewardship in the Hospital Setting
Antibiotic Stewardship in the Hospital Setting G. Evans, MD FRCPC Medical Director, Infection Prevention & Control Kingston General Hospital & Hotel Dieu Hospital EOPIC September 26, 2012 Stewardship stew-ard-ship
More informationClinical Review. Prevention and medical management of Clostridium difficile infection. J Shannon-Lowe, 1 N J Matheson, 2 F J Cooke, 1 S H Aliyu 1 2
For the full versions of these articles see bmj.com Clinical Review Prevention and medical management of Clostridium difficile infection J Shannon-Lowe, 1 N J Matheson, 2 F J Cooke, 1 S H Aliyu 1 2 1 Clinical
More informationMulti-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control
More informationClostridium difficile infection: The Present and the Future
Clostridium difficile infection: The Present and the Future Carlos E. Figueroa Castro, MD Assistant Professor, Division of Infectious Diseases Medical College of Wisconsin November 2014 I have made this
More informationPromoting Appropriate Antimicrobial Prescribing in Secondary Care
Promoting Appropriate Antimicrobial Prescribing in Secondary Care Stuart Brown Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England March 2015 Introduction Background ESPAUR
More informationMulti-Drug Resistant Organisms (MDRO)
Multi-Drug Resistant Organisms (MDRO) 2016 What are MDROs? Multi-drug resistant organisms, or MDROs, are bacteria resistant to current antibiotic therapy and therefore difficult to treat. MDROs can cause
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationPolicy for the Management of Clostridium Difficile
Policy for the Management of Clostridium Difficile Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. Policy Group Infection Control Committee Author Dr Linsey Batchelor
More informationSurveillance of Multi-Drug Resistant Organisms
Surveillance of Multi-Drug Resistant Organisms Karen Hoffmann, RN, MS, CIC Associate Director Statewide Program for Infection Control and Epidemiology (SPICE) University of North Carolina School of Medicine
More informationCDI Management in Post-Acute Care: Part 1
CDI Management in Post-Acute Care: Part 1 Robin Jump, MD, PhD VISN10 Geriatric Research Education and Clinical Center (GRECC) Louis Stokes Cleveland VA Medical Center Case Western Reserve University Robin.Jump@va.gov
More informationActive Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.
Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted
More informationLearning Objectives 6/1/18
Gulf Coast Multidisciplinary Pharmacotherapy Conference Kelly R. Reveles, PharmD, PhD, BCPS College of Pharmacy, The University of Texas at Austin School of Medicine, UT Health San Antonio Email: kdaniels46@utexas.edu
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationOptimizing Antimicrobial Stewardship Activities Based on Institutional Resources
Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov
More informationLINEE GUIDA: VALORI E LIMITI
Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions
More informationAntibiotic Stewardship in LTC What does this mean?
Antibiotic Stewardship in LTC What does this mean? Kieran Moore FCFP,FRCPC, Diane Lu CCFP KFLA Public Health Disclosure The findings and conclusions represent those of the presenter and may not necessarily
More information11/2/2015. Update on the Treatment of Clostridium difficile Infections. Disclosure. Objectives
Update on the Treatment of Clostridium difficile Infections Spencer H. Durham, Pharm.D.,BCPS (AQ-ID) Assistant Clinical Professor of Pharmacy Practice Auburn University Harrison School of Pharmacy Kurt
More informationNewsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017
Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t
More informationGlycopeptide Resistant Enterococci (GRE) Policy IC/292/10
BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 Supersedes: IC/292/07 Owner Name Dr Nicki Hutchinson Job Title Consultant Microbiologist,
More informationUPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM
UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health
More informationHealthcare-associated Infections Annual Report
September 2014 Healthcare-associated Infections Annual Report 2009-2013 Summary Provincial Infection Control Newfoundland Labrador (PIC-NL) has collected data on inpatients and outpatients with healthcare-associated
More informationSurgical prophylaxis for Gram +ve & Gram ve infection
Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance
More informationThe trinity of infection management: United Kingdom coalition statement
* The trinity of infection management: United Kingdom coalition statement This coalition statement, on behalf of our organizations (the UK Sepsis Trust, Royal College of Nursing, Infection Prevention Society,
More informationAntimicrobial Stewardship Strategy: Intravenous to oral conversion
Antimicrobial Stewardship Strategy: Intravenous to oral conversion Promoting the use of oral antimicrobial agents instead of intravenous administration when clinically indicated. Description This is an
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Report: 11 th August 2016 Issue: As part of ensuring compliance with the National Safety and Quality Health Service Standards (NSQHS), Yea & District Memorial Hospital is required
More informationMultidrug Resistant Organisms (MDROs) and Clostridium difficile (C. diff)
PATIENT & CAREGIVER EDUCATION Multidrug Resistant Organisms (MDROs) and Clostridium difficile (C. diff) This information explains multidrug resistant organisms (MDROs) and Clostridium difficile (C. diff),
More informationHorizontal vs Vertical Infection Control Strategies
GUIDE TO INFECTION CONTROL IN THE HOSPITAL Chapter 14 Horizontal vs Vertical Infection Control Strategies Author Salma Abbas, MBBS Michael Stevens, MD, MPH Chapter Editor Shaheen Mehtar, MBBS. FRC Path,
More informationInfection Control of Emerging Diseases
2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event
More informationCommunity-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018
Community-Associated C. difficile Infection: Think Outside the Hospital Maria Bye, MPH Epidemiologist Maria.Bye@state.mn.us 651-201-4085 May 1, 2018 Clostridium difficile Clostridium difficile Clostridium
More informationAn audit of the quality of antimicrobial prescribing
An audit of the quality of antimicrobial prescribing Rakhee Patel, Antimicrobial Pharmacist Alison Williams, Antimicrobial Technician & Dr Armando Gonzalez-Ruiz May 2011 ICE Score 2 Introduction & Aims
More informationQuality and Safety Committee
SUMMARY REPORT Quality and Safety Committee ABM University Health Board Meeting On 20 TH OCTOBER 2016 Subject Prepared by Approved & Presented by Purpose Big Fight Campaign AGENDA ITEM: 2.2 Debra Woolley
More informationGuideline Updates Change is Inevitable Especially in Infectious Diseases!
Guideline Updates Change is Inevitable Especially in Infectious Diseases! Vicky Shah, PharmD, BCPS Assistant Professor of Pharmacy Practice Wilkes University Nesbitt School of Pharmacy 1 Vicky Shah has
More informationAntimicrobial stewardship
Antimicrobial stewardship Magali Dodemont, Pharm. with the support of Wallonie-Bruxelles International WHY IMPLEMENT ANTIMICROBIAL STEWARDSHIP IN HOSPITALS? Optimization of antimicrobial use To limit the
More informationStudy Protocol. Funding: German Center for Infection Research (TTU-HAARBI, Research Clinical Unit)
Effectiveness of antibiotic stewardship interventions in reducing the rate of colonization and infections due to antibiotic resistant bacteria and Clostridium difficile in hospital patients a systematic
More informationScreening programmes for Hospital Acquired Infections
Screening programmes for Hospital Acquired Infections European Diagnostic Manufacturers Association In Vitro Diagnostics Making a real difference in health & life quality June 2007 HAI Facts Every year,
More informationClostridium difficile Surveillance Report 2016
Clostridium difficile Surveillance Report 2016 EMERGING INFECTIONS PROGRAM Clostridium difficile Surveillance Report 2016 Minnesota Department of Health Emerging Infections Program PO Box 64882, St. Paul,
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationEVIDENCE BASED MEDICINE: ANTIBIOTIC RESISTANCE IN THE ELDERLY CHETHANA KAMATH GERIATRIC MEDICINE WEEK
EVIDENCE BASED MEDICINE: ANTIBIOTIC RESISTANCE IN THE ELDERLY CHETHANA KAMATH GERIATRIC MEDICINE WEEK EPIDEMIOLOGY AND BACKGROUND Every year, more than 2 million people in the United States acquire antibiotic-resistant
More informationAntimicrobial Stewardship in the Hospital Setting
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 12 Antimicrobial Stewardship in the Hospital Setting Authors Dan Markley, DO, MPH, Amy L. Pakyz, PharmD, PhD, Michael Stevens, MD, MPH Chapter Editor
More informationPreventing Clostridium difficile. July 13,
Preventing Clostridium difficile Infection (CDI) July 13, 2011 1 Learning Objectives: Identify recent changes in the epidemiology of CDI, including transmission i and risk ikpopulations. Review recent
More informationAbout MRSA. MRSA (sometimes referred to as a superbug) stands for meticillin resistant Staphylococcus aureus.
About MRSA Other formats If you need this information in another format such as audio tape or computer disk, Braille, large print, high contrast, British Sign Language or translated into another language,
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Background Why Antimicrobial Stewardship 30-50% of antibiotic use in hospitals are unnecessary or inappropriate Appropriate antimicrobial use is a medication-safety and patient-safety
More informationAntibiotic stewardship in long term care
Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts
More informationMDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC
MDRO s, Stewardship and Beyond Linda R. Greene RN, MPS, CIC linda_greene@urmc.rochester.edu Evolving Threat of Antimicrobial Resistance Why are MDROs important? Limited treatment options Associated with:
More informationCarbapenemase-Producing Enterobacteriaceae (CPE)
Carbapenemase-Producing Enterobacteriaceae (CPE) September 21, 2017 Maryam Khan Peel Public Health Madeleine Ashcroft Public Health Ontario Objectives Differentiate the acronyms related to CPE (CPE,CPO,CRE,CRO)
More informationYour Guide to Managing. Multi Drug-resistant Organisms (MDROs)
Agency for Integrated Care 5 Maxwell Road #10-00 Tower Block MND Complex Singapore 069110 Singapore Silver Line: 1800-650-6060 Email: enquiries@aic.sg Website: www.silverpages.sg Facebook: www.facebook.com/carerssg
More informationInfection Control & Prevention
Infection Control & Prevention Objectives: Define the term multi-drug resistant organism (MDRO). Recognize risk factors for developing MDROs. Describe the clinical manifestations and medical treatment
More informationThe Core Elements of Antibiotic Stewardship for Nursing Homes
The Core Elements of Antibiotic Stewardship for Nursing Homes APPENDIX B: Measures of Antibiotic Prescribing, Use and Outcomes National Center for Emerging and Zoonotic Infectious Diseases Division of
More informationClostridium difficile Colitis
1 Clostridium difficile Colitis William R. Sonnenberg, MD 2 Disclosure Dr. Sonnenberg has no conflict of interest, financial agreement, or working affiliation with any group or organization. 3 Learning
More informationAntibiotic Stewardship in the Neonatal Intensive Care Unit. Objectives. Background 4/20/2017. Natasha Nakra, MD April 28, 2017
Antibiotic Stewardship in the Neonatal Intensive Care Unit Natasha Nakra, MD April 28, 2017 Objectives 1. Describe antibiotic use in the NICU 2. Explain the role of antibiotic stewardship in the NICU 3.
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Hand Hygiene CHAPTER 6: Authors A. J. Stewardson, MBBS, PhD D. Pittet, MD, MS
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 6: Hand Hygiene Authors A. J. Stewardson, MBBS, PhD D. Pittet, MD, MS Chapter Editor Shaheen Mehtar, MD, MBBS, FRC Path, FCPath (Micro) Topic Outline
More informationSection 10: Antimicrobial Stewardship and Clostridium difficile Infection: A Primer for the Infection Preventionist
Section 10: Antimicrobial Stewardship and Clostridium difficile Infection: A Primer for the Infection Preventionist Antimicrobial stewardship may be a relatively new addition to the job responsibilities
More informationMRSA in the United Kingdom status quo and future developments
MRSA in the United Kingdom status quo and future developments Dietrich Mack Chair of Medical Microbiology and Infectious Diseases The School of Medicine - University of Wales Swansea P R I F Y S G O L
More informationAntibiotic therapy of acute gastroenteritis
Antibiotic therapy of acute gastroenteritis Potential goals Clinical improvement (vs control) Fecal eradication of the pathogen and decrease infectivity Prevent complications Acute gastroenteritis viruses
More informationNorth West Neonatal Operational Delivery Network Working together to provide the highest standard of care for babies and families
Document Title and Reference : Guideline for the management of multi-drug resistant organisms (MDRO) Main Author (s) Simon Power Ratified by: GM NSG Date Ratified: February 2012 Review Date: March 2017
More information11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose
Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University
More information28/08/2017. Infection Prevention and Control. Safe Patient Care Bugs and Drugs The ongoing challenge of MDROs and AMR
Safe Patient Care Bugs and Drugs The ongoing challenge of MDROs and AMR 2017 Safe Patient Care 2017: The Ongoing Challenge of MDROs and AMR Management of the Patient Environment in relation to Multidrug
More informationWhy Antimicrobial Stewardship?
Antimicrobial Stewardship: Why and How CAPT Arjun Srinivasan, MD Associate Director for Healthcare Associated Infection Prevention Programs Division of Healthcare Quality Promotion Why Antimicrobial Stewardship?
More informationAntimicrobial Stewardship Strategy:
Antimicrobial Stewardship Strategy: Prospective audit with intervention and feedback Formal assessment of antimicrobial therapy by trained individuals, who make recommendations to the prescribing service
More informationMethicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship
Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Natalie R. Tucker, PharmD Antimicrobial Stewardship Pharmacist Tyson E. Dietrich, PharmD PGY2 Infectious Diseases
More informationClostridium difficile Infection: An Update on the Current State of Prevention
Intermountain APIC and Qualis Health present I-APIC HAI Prevention Learning Network Webinar Series Clostridium difficile Infection An Update on the April 11, 2012 Ruth CarricoPhD RN FSHEA CIC Clostridium
More informationBoard Meeting Agenda Item: 7.2 Paper No: Purpose: For Information. Healthcare Associated Infection Report
Board Meeting 9.. Agenda Item: 7. Paper No: 6- Purpose: For Information Healthcare Associated Infection Report August/September Board Meeting 9.. Agenda Item: 7. Paper No: 6- Purpose: For Information August/September
More information8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM
Mary Moore, MS CIC MT (ASCP) Infection Prevention Coordinator Great River Medical Center, West Burlington REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM ABOUT
More informationHealth Service Executive Parkgate St. Business Centre, Dublin 8 Tel:
Health Service Executive Parkgate St. Business Centre, Dublin 8 Tel: 01 635 2500 www.hse.ie Health Service Executive Oak House, Millennium Park, Naas, Co. Kildare Tel: 045 880 400 www.hse.ie The prevention
More informationThe Epidemiology Of Clostridium Difficile Infections Among Oncology Patients
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Public Health Theses School of Public Health January 2015 The Epidemiology Of Clostridium Difficile Infections Among Oncology
More informationClostridium difficile may be found in 1% to 3% of all
ORIGINAL ARTICLE Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients Kruti Shah, PharmD, BCPS, Leigh Ann Pass, PharmD, BCPS, Mark Cox, PharmD,
More informationA patient s guide to. MRSA - Methicillin Resistant Staphylococcus Aureus
A patient s guide to MRSA - Methicillin Resistant Staphylococcus Aureus 1 What is MRSA? There are lots of micro-organisms (germs) on our skin. They are in the air we breathe, the water we drink, and the
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationHealthcare-associated Infections Annual Report March 2015
March 2015 Healthcare-associated Infections Annual Report 2009-2014 TABLE OF CONTENTS SUMMARY... 1 MRSA SURVEILLANCE RESULTS... 1 CDI SURVEILLANCE RESULTS... 1 INTRODUCTION... 2 METHICILLIN-RESISTANT
More informationAssessment of empirical antibiotic therapy in a tertiary-care hospital: An observational descriptive study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 9 Ver. VI (September). 2016), PP 118-124 www.iosrjournals.org Assessment of empirical antibiotic
More informationImplementing Antibiotic Stewardship in Rural and Critical Access Hospitals
National Center for Emerging and Zoonotic Infectious Diseases Implementing Antibiotic Stewardship in Rural and Critical Access Hospitals Denise Cardo, MD Director, Division of Healthcare Quality Promotion,
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationCall-In Number: (888) Access Code:
EDUCATIONAL SERIES: Navigating Infection Control and Antimicrobial Stewardship in Long-Term Care Webinar #2: Introduction to Antimicrobial Stewardship in Long Term Care: What is Antimicrobial Stewardship
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationAntibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE
Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE Crisis: Antibiotic Resistance Success Strategy WWW.optimistic-care.org
More informationTaking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms
Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms Nimalie D. Stone, MD,MS Division of Healthcare Quality Promotion National
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More informationClostridium difficile: Review of Treatment & Prevention through Antimicrobial Stewardship
Clostridium difficile: Review of Treatment & Prevention through Antimicrobial Stewardship Kim Van Wyk, Pharm.D., BCPS Mountain-Pacific Quality Health Objectives Review epidemiology of Clostridium diffilcile
More informationImpact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis
ORIGINAL ARTICLE EPIDEMIOLOGY Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis J. Price 1, E. Cheek 2,
More informationAntibiotic Stewardship at MetroWest Medical Center. Colleen Grocer, RPh, BCOP Co-Chair, Antibiotic Stewardship Committee
Antibiotic Stewardship at MetroWest Medical Center Colleen Grocer, RPh, BCOP Co-Chair, Antibiotic Stewardship Committee Antibiotic Stewardship Committee Subcommittee of Pharmacy and Therapeutics. Also
More informationGeriatric Mental Health Partnership
Geriatric Mental Health Partnership September 8, 2017 First, let s test your knowledge about antibiotics http://www.cdc.gov/getsmart/community/about/quiz.html 2 Get Smart Antibiotics Quiz Antibiotics fight
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Preventing the Spread of Antibiotic Resistance and Improving Patient Care (Adapted from the Centers for Disease Control and Prevention) What is Stewardship? Antimicrobial stewardship
More informationMAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges
Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control
More informationMDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta
MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental
More information